Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)Alba A. Brandes, Mario Ermani|British Journal of Cancer|2006Cited by 228
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)Enrico Franceschi, Alba A. Brandes, Benedetta Urbini et al.|British Journal of Cancer|2007Cited by 212
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancerMaria Vittoria Dieci, Valentina Guarneri, PierFranco Conte et al.|Annals of Oncology|2019Cited by 96
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75